Dr. Eyad Elkord's Group

Dr Elkord’s research group focuses on Cancer Immunology and Immunotherapy and the use of different immunotherapeutic modalities for treating cancer. More specifically our group is interested in:
  • Investigating the mechanisms employed by tumors to evade immune-mediated destruction with special interest in the role and function of immunosuppressive cells [T regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs)] in cancer. Recent evidences indicate that immunosuppressive cells are implicated in the immunopathology of cancer and their specific targeting may improve the efficacy of immunotherapeutic modalities. We showed that Tregs are expanded in peripheral blood and tumor microenvironment of cancer patients, which correlated with poor prognosis and reduced survival. Our recent work has further established that Treg infiltration of tumors is correlated with a lack of some patients’ responsiveness to therapy. Additionally, we found that adoptive transfer of Treg-depleted autologous T cells in renal cell carcinoma patients following conditioning chemotherapy provided a transient reduction of circulating Treg levels which was associated with improved antitumor immune response to the tumor-associated antigen.
  • Interaction and mechanisms utilised by tumors to induce and/or expand immunosuppressive cells (Tregs and MDSCs).
  • Investigating potential and novel markers for discriminating the different Treg subsets including thymic and peripherally induced Tregs.
  • Differential characterization of T regulatory cells in cancer patients compared to healthy individuals.
  • Investigating Treg-specific markers as potential therapeutic targets in cancer.
  • Investigating the cellular immunity to human tumor-associated antigens and discovering MHC class I and II epitopes derived from these antigens.
  • Identification and isolation of tumor-specific T effector cells and investigating potential strategies for improving antitumor-specific immune responses.
  • Investigating the mechanism of action of anti-cancer therapies.
  • Undertaking research activities in connection with immunotherapeutic clinical trials and cancer immunobiology.
  • Investigating immune regulation and immune monitoring of clinical trials involving different immunotherapeutic modalities..

Eyad Elkord's Group Currently approved and experimental therapies that may target T regulatory cells; therapies are color-coded according to stage in clinical testing.
Abbreviations – ADCC: antibody-dependent cell-mediated cytotoxicity, ADCP: antibody-dependent cellular phagocytosis, ATZB: atezolizumab, BV: bevacizumab, CTX: cyclophosphamide, DC: dendritic cell, DZB: daclizumab, CCR4: C-C motif chemokine receptor 4, DPT: diphtheria toxin, FDB: fludarabine, IPB: ipilimumab, MGZ: mogamulizumab, NIVO: nivolumab, ONTAK: denileukin difitox, PTX: paclitaxel, SNB: sunitinib.

Dr. Eyad Elkord's Group

Back to Top